share_log

HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $11 Price Target

HC Wainwright & Co.重申買入 CARISMA Therapeutics,維持11美元的目標股價
Benzinga ·  2023/11/29 06:28

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $11 price target.

HC Wainwright & Co. 分析師米切爾·卡普爾重申了CARISMA Therapeutics(納斯達克股票代碼:CARM)的買入並維持11美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論